SRC
NAVB

Sage Rhino Capital’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Sage Rhino Capital’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-700
Closed -$2K – 139
2019
Q1 		$2K Buy
+700
New +$2.06K ﹤0.01% 127

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sage Rhino Capital's NAVB Position: Q2 2019 in Review

Sage Rhino Capital sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2019, closing a stake of 700 shares — an estimated $2K sold.

Sage Rhino Capital first reported a position in NAVB in Q1 2019 and held it in 1 quarter. The position peaked at $2K in Q1 2019. 27 funds tracked by Wall St. Rank hold NAVB as of Q2 2019.

  • Sage Rhino Capital reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2019 after selling out during the quarter.
  • Sage Rhino Capital sold 700 Navidea Biopharmaceuticals Inc. shares in Q2 2019, an estimated $2K.
  • Sage Rhino Capital first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2019 and held it in 1 quarter.
  • Sage Rhino Capital's Navidea Biopharmaceuticals Inc. position peaked at $2K in Q1 2019.
  • 27 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2019.

Based on Sage Rhino Capital's 13F filing for Q2 2019, filed 20 Aug 2019.